During this unique study, led by the University of Glasgow and University of Surrey, researchers investigated how the experience of COPD, influences how individuals understand new or changing chest symptoms and their decision to seek help from medical professionals. COPD is the name for a group of lung conditions, including emphysema and chronic bronchitis, which...
Tag: <span>Lung cancer</span>
Post
Raising awareness of lung cancer risk in people with COPD
People with chronic obstructive pulmonary disease (COPD) need more support when understanding and acting on new chest symptoms, a study in the journal Psycho-Oncologyreports. Credit: CC0 Public Domain During this unique study, led by the University of Glasgow and University of Surrey, researchers investigated how the experience of COPD, influences how individuals understand new or...
Post
First line immunotherapy combination fails to improve overall survival in lung cancer
ESMO Immuno-Oncology Congress, Dec. 13-16, Geneva, Switzerland EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY Geneva, Switzerland, 13 December 2018 – First line Immunotherapy with durvalumab or the combination of durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer, according to late breaking results from the MYSTIC trial presented at the ESMO Immuno-Oncology...
Post
Researchers extend effectiveness of immunotherapy to more lung cancer patients
Immunotherapy, the strategy for triggering the patient’s own immune system to attack cancer, is proving effective for more tumour types, although to varying degrees. In lung cancer, immunotherapy had proven to extend survival rates for only some variants of the disease. Now, an international clinical trial led by the oncologist Luis Paz-Ares has substantially increased...
Post
Proposed cancer treatment may boost lung cancer stem cells, study warns
Study adds evidence that cancer stem cells drive adenocarcinoma; suggests new strategy that makes tumor cells less “stem-like” BOSTON CHILDREN’S HOSPITAL Epigenetic therapies — targeting enzymes that alter what genes are turned on or off in a cell — are of growing interest in the cancer field as a way of making a cancer less...
Post
Will tarloxotinib finally break the HER2 barrier in lung cancer?
The HER2 gene is a well-known driver of breast cancer, where changes in this gene are found in about 1-in-5 cases of the disease. HER2 also contributes to about 3 percent of lung cancers, representing about 6,500 patients per year. But while drugs like trastuzumab and lapatinib have proven effective in silencing the action of...
Post
New method uses just a drop of blood to monitor lung cancer treatment
Dr. Tasuku Honjo won the 2018 Nobel Prize in physiology or medicine for discovering the immune T-cell protein PD-1. This discovery led to a set of anti-cancer medications called checkpoint inhibitors, one of the first of which was nivolumab (Opdivo). Nivolumab helps T-cells fight tumors, however, different patients respond in different ways. It now appears...
Post
Brigatinib becomes potential new first-line option for ALK-positive non-small lung cancer
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2018 argue for brigatinib as a first-line treatment option for advanced...
Post
Dental research shows that smoking weakens immune systems
As if lung cancer, emphysema and heart disease weren’t enough, there’s more bad news for cigarette smokers. Researchers at the Case Western Reserve University School of Dental Medicine found that smoking also weakens the ability for pulp in teeth to fight illness and disease. In other words, smokers have fewer defense mechanisms on the inside...
Post
New finding could ‘pause and rewind’ lung cancer
A team of Institute researchers has discovered how to stop and reverse the growth of lung cancer with a potent combination of three molecules. Lung CA seen on CXR. Credit: James Heilman, MD/Wikipedia The study found that two BH3-mimetics and one FGFR inhibitor were able to block lung cancer cell survival so successfully in pre-clinical models that tumors not...